• Login
    View Item 
    •   BEARdocs Home
    • Graduate School
    • Electronic Theses and Dissertations
    • View Item
    •   BEARdocs Home
    • Graduate School
    • Electronic Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Anti-CD47 targeting therapy for the treatment of colon and pancreas cancers.

    View/Open
    CHA-DISSERTATION-2016.pdf (86.54Mb)
    Adriel_Cha_copyrightavailabilityform.pdf (1.172Mb)
    SHERPA_RoMEO - Gene.pdf (139.4Kb)
    SHERPA_RoMEO - Laboratory Investigation.pdf (140.3Kb)
    SHERPA_RoMEO - Clinical Cancer Research.pdf (136.7Kb)
    Access rights
    Worldwide access.
    Access changed 7/31/20.
    Date
    2016-03-10
    Author
    Cha, Adriel C., 1985-
    Metadata
    Show full item record
    Abstract
    CD47 is a “don’t eat me” signal over expressed on cancer cells inhibiting their engulfment by phagocytes. A novel monoclonal antibody, Hu5F9-G4, blocking CD47’s interaction with its ligand SIRPα allowed for phagocytosis of colorectal and pancreas tumors by macrophages. In some models, treatment of xenotransplanted tumors in immunodeficient mice with anti-CD47 antibodies strongly reduced tumor growth. In other models, the combination of anti-CD47 and anti-EGFR antibodies regressed tumor burden, where neither single agent therapy was as effective. Even in KRAS mutated tumors, where use of anti-EGFR antibodies is not indicated, the combination of antibodies lead to major tumor reduction. Taken collectively, Hu5F9-G4 is an effective treatment in colorectal and pancreas cancers, and in the combination of Hu5F9-G4 with an anti-EGFR antibody is therapeutically effective in KRAS mutated tumors in mouse xenografts. Cancer immunotherapy, including anti-CD47 blockade, tries to utilize the host’s own immune system to mount an immune response to cancer. To date, there have been a multitude of new therapies from cytokine treatments, to cell based vaccines, to antibody therapies which all recruit immune cells that have been somehow silenced by the tumor microenvironment. The Weissman lab’s own studies into the adaptive immune system suggest that upon phagocytosis, mediated by anti-CD47 antibodies, the subsequent T cell presentation preferentially recruits cytotoxic T cells. Here, we propose two additional model systems to further investigate the role CD47 plays in antigen presentation and downstream T cell recruitment to target cancer cells. Recent advances with immunotherapy agents for the treatment of cancer has provided remarkable, and in some cases, curative results. Blockade of the CD47:SIRPα axis between tumor cells and innate immune cells increases tumor cell phagocytosis in both solid tumors and hematological malignancies. These phagocytic innate cells are also professional antigen presenting cells, providing a link from innate to adaptive anti-tumor immunity. Preliminary studies have demonstrated that APCs present antigens from phagocytosed tumor cells, causing T cell activation. Therefore, agents that block CD47:SIRP-α engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune modulating agents for activating anti-tumor T cells in vivo.
    URI
    http://hdl.handle.net/2104/9649
    Collections
    • Electronic Theses and Dissertations
    • Theses/Dissertations - Biomedical Studies

    Copyright © Baylor® University All rights reserved. Legal Disclosures.
    Baylor University Waco, Texas 76798 1-800-BAYLOR-U
    Baylor University Libraries | One Bear Place #97148 | Waco, TX 76798-7148 | 254.710.2112 | Contact: libraryquestions@baylor.edu
    If you find any errors in content, please contact librarywebmaster@baylor.edu
    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    TDL
    Theme by 
    Atmire NV
     

     

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Login

    Statistics

    View Usage Statistics

    Copyright © Baylor® University All rights reserved. Legal Disclosures.
    Baylor University Waco, Texas 76798 1-800-BAYLOR-U
    Baylor University Libraries | One Bear Place #97148 | Waco, TX 76798-7148 | 254.710.2112 | Contact: libraryquestions@baylor.edu
    If you find any errors in content, please contact librarywebmaster@baylor.edu
    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    TDL
    Theme by 
    Atmire NV